Reportlinker Adds Triple Analysis: Lymphoma, Cancer Vaccines and Antibodies
NEW YORK, Oct. 19 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Triple Analysis: Lymphoma, Cancer Vaccines and Antibodies
http://www.reportlinker.com/p0284881/Triple-Analysis-Lymphoma-Cancer-Vaccines-and-Antibodies.html
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Lymphoma), one mechanism/target/effect area (Cancer Vaccines) and one compound specific area (Antibodies). Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.
Below is a short synopsis of each part included in this report:
Part I: Lymphoma
The lymphoma report part includes defined and up to date development strategies for 176 lymphoma therapeutic drugs (>230 projects) within the portfolio of 106 investigators, from Ceased to Marketed. In total the report assesses five different sub-indications of lymphoma (B-cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, T-cell lymphoma and Lymphoma (general)). This report part extensively analyses 124 identified targets of lymphoma drugs, organized into 109 drug target strategies, and assesses them in lymphoma.
This part is based on the following publication:
Lymphoma Drug Development Strategies at Work - Define Your Competition
Part II: Cancer Vaccines
The cancer vaccine report part comprises defined and up to date development strategies for 155 cancer vaccine drugs within the portfolio of 99 investigators, from Ceased to Marketed. This part extensively analyses their 94 identified drug targets, organized into 91 drug target strategies, and assesses them in 42 different cancer indications.
This part is based on the following publication:
Commercializing Cancer Vaccines: A Decision Support Tool for Optimizing the Pipeline
Part III: Antibodies
The antibody report part comprises defined and up to date development strategies for 441 antibody drugs (993 projects) within the portfolio of 168 investigators, from Ceased to Marketed. This report part extensively analyses 225 identified targets of antibody drugs, organized into 234 drug target strategies, and assesses them in 69 different cancer indications.
This part is based on the following publication:
Antibody Drug Target Atlas in Oncology - Where to Commercialize in a Crowded Market Place?
The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies' pipeline and portfolio planning (PPP) in cancer by:
* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives
* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug's properties
* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities
* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities
* Supporting development of integrative molecule, pathway and disease area strategies
* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment
This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.
Key Topics Covered:
Part I: Lymphoma
5.1 The Scope of this Report 22
6 Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment (124 Drug Targets) 26-250
7 The Rise of New Products: How Mature, Unique and Clinically Validated are the Drug Target Profiles Identified in the Lymphoma Pipeline? (109 Drug Target Strategies and 176 Drugs) 251-280
8 Compound Strategies at Work: Competitive Benchmarking of Lymphoma Pipeline by Type of Compound (6 Different Compound Strategies) 281-312
9 Selecting a Sub-Indication of Lymphoma for Drug Development 313-450
10 Portfolio Planning: Competitive Benchmarking of Lymphoma Pipeline by Investigator (106 Investigators) 351-524
12 Drug Index 526
13 Company Index 531
Figures: Includes 17 Figures
Tables: Includes 164 Tables
Total Number of Pages: 535
Part II: Cancer Vaccines
5.1 The Scope of this Report 26
6 Consider the Therapeutic Target Among Cancer Vaccine Drugs for the Highest Therapeutic Outcome and Return on Investment (94 Drug Targets) 30-194
7 Emerging New Products to Established Ones: Drug Target Strategies of Cancer Vaccine Drugs by their Highest Stage of Development (91 Drug Target Strategies and 155 Cancer Vaccine Drugs) 195-308
8 Compound Strategies at Work: Competitive Benchmarking of Cancer Vaccine Drugs by Compound Strategy (7 Compound Strategies) 309-338
9 Selecting Cancer Indications for Cancer Vaccine Drugs (42 Cancer Indications) 339-386
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Vaccine Drug Pipeline by Investigator (99 Investigators) 387-649
11 Disclaimer 650
12 Drug Index 651
13 Company Index 656
Figures: Includes 6 Figures
Tables: Includes 205 Tables
Total Number of Pages: 659
Part III: Antibodies
5.2 The Scope of this Report 30
6 Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment (225 Drug Targets) 36-319
7 The Rise of New Products: How Mature, Unique and Clinically Validated are the Drug Target Profiles Identified in the Cancer Antibody Therapeutic Pipeline? (234 Drug Target Strategies and 441 Drugs) 320-383
8 Selecting Cancer Indications for Antibody Therapeutics (69 Different Cancer Indications) 384-499
9 Portfolio Planning: Competitive Benchmarking of Antibody Cancer Therapeutic Pipeline by Investigator (168 Investigators) 500-1268
11 Drug Index 1270
12 Company Index 1282
Figures: Includes 5 Figures
Tables: Includes 302 Tables
Total Number of Pages: 1289
To order this report:
Drug Discovery and Development Industry: Triple Analysis: Lymphoma, Cancer Vaccines and Antibodies
Drug Discovery and Development Business News
Check our Company Profile, SWOT and Revenue Analysis!
CONTACT:
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article